Genmab and Incyte are combining three attacks on KRAS-mutant colorectal cancer, but can they overcome EGFR resistance?
Genmab and Incyte will test petosemtamab with a KRAS G12D inhibitor in metastatic colorectal cancer. Can dual pathway targeting overcome resistance?
